Neonatal Fc receptor (FcRn) antagonists are a novel, highly specific, and effective targeted treatment option for patients with generalized myasthenia gravis (gMG). FcRn antagonists are not only revolutionizing the treatment landscape of gMG, but also offer the opportunity for individualized treatment. With two recent approvals and several therapies in late phase 3 trials, FcRn antagonists hold promise as an effective option for reducing the burdens associated with gMG. In this second of two videos, join two experts in a discussion focused on the latest clinical evidence on FcRn antagonists, opportunities for individualized dosing strategies, and effective methods of disease monitoring and treatment-related adverse event management. You will also gain immediate access to a downloadable point-of-care resource to support the appropriate application of targeted therapies and individualized treatment strategies in your practice to help aid in providing keys to proper application of targeted therapies in gMG and strategies for individualized treatment.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/advancing-gmg-management-integrating-latest-evidence-into-personalized-care
- Start Date: 2025-01-10 06:00:00
- End Date: 2025-01-10 06:00:00
- Credit Details: IPCE Credits: 0.5 hours
AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - Commercial Support: Source: Argenx US, Inc. - Amount: 50000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all